Dexcel Pharma is a privately-held, international specialty pharmaceutical company, employing over 1,000 people, with a presence in 20 countries worldwide, including subsidiaries in the US, UK and Germany.
 
Dexcel Pharma's portfolio consists of more than 55 branded and generic products in over 140 dosages, with 2011 sales of 5 billion tablets/capsules, totaling US$270 milllion. Around 85% of sales are to the large international markets.

Dexcel Pharma is the 2nd largest Israeli pharmaceutical manufacturer, supplying 25% of the branded and generic pharmaceuticals sold in Israel.

Dexcel Pharma’s corporate HQ, R&D and newly-expanded manufacturing facilities are in Or Akiva, Israel, with a new, state of the art, 5-floor gravity feed, paperless, electronic manufacturing plant of tablets/capsules in Yokneam, and an R&D site in Jerusalem (see Manufacturing Facilities).

Dexcel Pharma is fully owned and controlled by its founder, President and CEO, Dan Oren.

Dexcel Pharma celebrated the 40th anniversary of its founding in September 2008.